Cutting Edge Fundraising

THM Capital Advisory is supporting Cutting Edge in strengthening its equity capital in order to strengthen its capacity to produce hydrophobic intraocular implants and to accelerate its international development.

Activity

Cutting Edge designs, produces and markets intraocular implants for the treatment of cataracts. Founded in 2015 and based in Labège (31), the company has developed a complete range of implants and obtained 9 CE markings for the marketing of its products.

Historically specialized in hydrophilic polymer implants, Cutting Edge is now extending its offer to hydrophobic polymer implants, whose global demand is growing rapidly.

Objectives

Cutting Edge is raising funds to increase its production capacity for hydrophobic implants, accelerate its growth in France and abroad in around twenty countries, then continue its geographical expansion and the extension of its product range (new R&D developments or targeted acquisitions).

Investors

A family office resulting from a chemical group developing and producing polymers.